Ampatzoglou Antonis, Gruszecka-Kosowska Agnieszka, Torres-Sánchez Alfonso, López-Moreno Ana, Cerk Klara, Ortiz Pilar, Monteoliva-Sánchez Mercedes, Aguilera Margarita
Department of Microbiology, Faculty of Pharmacy, University of Granada (UGR), Granada, Spain.
Centre of Biomedical Research, Institute of Nutrition and Food Technology "José Mataix" (INYTA), UGR, Granada, Spain.
Front Microbiol. 2022 May 4;13:872583. doi: 10.3389/fmicb.2022.872583. eCollection 2022.
Three areas of relevance to the gut microbiome in the context of One Health were explored; the incorporation of the microbiome in food safety risk assessment of xenobiotics; the identification and application of beneficial microbial components to various areas under One Health, and; specifically, in the context of antimicrobial resistance. Although challenging, focusing on the microbiota resilience, function and active components is critical for advancing the incorporation of microbiome data in the risk assessment of xenobiotics. Moreover, the human microbiota may be a promising source of beneficial components, with the potential to metabolize xenobiotics. These may have possible applications in several areas, e.g., in animals or plants for detoxification or in the environment for biodegradation. This approach would be of particular interest for antimicrobials, with the potential to ameliorate antimicrobial resistance development. Finally, the concept of resistance to xenobiotics in the context of the gut microbiome may deserve further investigation.
探讨了在“同一个健康”背景下与肠道微生物群相关的三个领域;将微生物群纳入异生物素的食品安全风险评估;在“同一个健康”框架下,确定有益微生物成分并将其应用于各个领域,特别是在抗菌药物耐药性方面。尽管具有挑战性,但关注微生物群的恢复力、功能和活性成分对于推动将微生物组数据纳入异生物素风险评估至关重要。此外,人类微生物群可能是有益成分的一个有前景的来源,具有代谢异生物素的潜力。这些成分可能在几个领域有潜在应用,例如在动物或植物中用于解毒,或在环境中用于生物降解。这种方法对于抗菌药物特别有意义,有可能改善抗菌药物耐药性的发展。最后,肠道微生物群背景下对异生物素的耐药性概念可能值得进一步研究。